Use of sibutramine analogues to prevent the development of diabetes
Patent 6174925 Issued on January 16, 2001. Estimated Expiration Date: 
March 17, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 17, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMedical treatment Improving glucose tolerance Patent #: 5942549 InventorsAssigneeApplicationNo. 254924 filed on 03/17/1999US Classes:514/646, Benzene ring containing514/866DIABETESExaminersPrimary: Weddington, Kevin E.Attorney, Agent or FirmForeign Patent References
International ClassA61K 031/135Foreign Application Priority Data1996-09-21 GBAbstractA compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for reducing Insulin resistance in humans in whom Impaired Glucose Tolerance and Non-Insulin Dependent Diabetes Mellitus have not presented.Other References
| |
